
|Articles|July 1, 2001
- Pharmaceutical Executive-07-01-2001
- Volume 0
- Issue 0
Generic Threat
Author(s)Kevin Gopal
Epsom, Surrey, United Kingdom—Pharmaceutical companies struggle to be taken seriously when they talk of facing pressures. A quick look at the bottom line often suggests they are overstating their worries. But new evidence shows they are being squeezed by generic competition and falling R&D output.
Advertisement
Articles in this issue
almost 25 years ago
Pharmacies: OTC Price Warsalmost 25 years ago
One Disease at a Timealmost 25 years ago
Overview of the Industry: A World of Opportunitiesalmost 25 years ago
The Power Shiftalmost 25 years ago
A Giant Stumblesalmost 25 years ago
Overruled: No More Dual Pricingalmost 25 years ago
SubmergedNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Medical Supply Chains at Risk Over Escalating Conflicts in Iran: Report
2
Novavax Stock Increases as Shah Capital Plans to Vote Against Board Nominees
3
What Unexpected Costs do GLP-1 Patients Face?
4
Q&A: Supply Chain Fallout From Iran War, Tariff Uncertainty
5




